December 23, 2025 –Polpharma Biologics is pleased to acknowledge the recent announcement of Bioeq AG, our joint venture, regarding the licensing, supply, and commercialization agreement with Zydus Lifesciences Ltd. for NUFYMCO® (biosimilar ranibizumab), an interchangeable biosimilar to Lucentis®, in the United States.
This strategic collaboration underlines the strength and expertise of Polpharma Biologics as a Bioeq shareholder in partnership with Formycon AG through Bioeq AG.
Under the agreement, Bioeq will oversee the development, manufacturing, registration and supply of the finished product, while Zydus Lifesciences will be responsible for commercialization in the U.S. market.
The Biologics License Application (BLA) for NUFYMCO® has been approved by the U.S. Food and Drug Administration (USFDA), representing a significant milestone in expanding access to high-quality, affordable ophthalmology treatments in the United States.
Polpharma Biologics is proud to contribute its advanced scientific and manufacturing capabilities to the offering of complex biosimilar medicines for highly regulated markets. This partnership further demonstrates our commitment to improving healthcare accessibility and patient outcomes by providing cost-effective alternatives to leading biologics.
We look forward to supporting the continued growth and success of NUFYMCO® and to the positive impact this collaboration will have on expanding treatment options for patients in the U.S.
